IP Verse

Binding Molecules For Bcma And Cd3 - EP2780374

The patent EP2780374 was granted to Amgen on Aug 21, 2019. The application was originally filed on Nov 15, 2012 under application number EP12803509A. The patent is currently recorded with a legal status of "Revoked".

EP2780374

AMGEN
Application Number
EP12803509A
Filing Date
Nov 15, 2012
Status
Revoked
Aug 25, 2023
Grant Date
Aug 21, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KONIG SZYNKA TILMANN VON RENESSEMay 22, 2020KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE
JAMES POOLEMay 21, 2020CARPMAELS & RANSFORDADMISSIBLE
MATHYS & SQUIREMay 21, 2020MATHYS & SQUIREADMISSIBLE
REGENERON PHARMACEUTICALSMay 21, 2020CARPMAELS & RANSFORDADMISSIBLE
SANOFIMay 20, 2020HOFFMANN EITLEADMISSIBLE
PFIZERMay 4, 2020PFIZERADMISSIBLE
JANSSEN BIOTECHApr 14, 2020CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (69) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0171496
DESCRIPTIONEP0173494
DESCRIPTIONEP0183070
DESCRIPTIONEP0239400
DESCRIPTIONEP0244234
DESCRIPTIONEP0402226
DESCRIPTIONEP1019141
DESCRIPTIONGB2177096
DESCRIPTIONUS1985
DESCRIPTIONUS2003070185
DESCRIPTIONUS4485045
DESCRIPTIONUS4544545
DESCRIPTIONUS4816397
DESCRIPTIONUS4816567
DESCRIPTIONUS4816
DESCRIPTIONUS4946778
DESCRIPTIONUS5013556
DESCRIPTIONUS5223409
DESCRIPTIONUS5225539
DESCRIPTIONUS5565332
DESCRIPTIONUS5585089
DESCRIPTIONUS5648260
DESCRIPTIONUS567
DESCRIPTIONUS5693761
DESCRIPTIONUS5693762
DESCRIPTIONUS5859205
DESCRIPTIONUS6300064
DESCRIPTIONUS6407213
DESCRIPTIONWO0034317
DESCRIPTIONWO02066516
DESCRIPTIONWO2007042261
DESCRIPTIONWO2008119567
DESCRIPTIONWO9633735
DESCRIPTIONWO9634096
DESCRIPTIONWO9738731
DESCRIPTIONWO9852976
DESCRIPTIONWO9954440
INTERNATIONAL-SEARCH-REPORTWO0187977
INTERNATIONAL-SEARCH-REPORTWO02066516
INTERNATIONAL-SEARCH-REPORTWO2004106383
INTERNATIONAL-SEARCH-REPORTWO2009132058
INTERNATIONAL-SEARCH-REPORTWO2012066058
OPPOSITIONEP1210425
OPPOSITIONEP1223964
OPPOSITIONEP1806143
OPPOSITIONEP2640750
OPPOSITIONEP2780375
OPPOSITIONUS2007212733
OPPOSITIONUS9150664
OPPOSITIONUS9340621
OPPOSITIONWO0040716
OPPOSITIONWO0112812
OPPOSITIONWO0124811
OPPOSITIONWO0187977
OPPOSITIONWO02066516
OPPOSITIONWO2004106383
OPPOSITIONWO2005040220
OPPOSITIONWO2005061547
OPPOSITIONWO2007042261
OPPOSITIONWO2008119565
OPPOSITIONWO2008119566
OPPOSITIONWO2008119567
OPPOSITIONWO2009132058
OPPOSITIONWO2010037835
OPPOSITIONWO2010037836
OPPOSITIONWO2010037837
OPPOSITIONWO2010037838
OPPOSITIONWO2010104949
OPPOSITIONWO2012066058

Non-Patent Literature (NPL) Citations (63) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- (20110803), URL: https://web.archive.org/web/20110803071256/https://www.uniprot.org/uni prot/Q02223-
OPPOSITION- A Neisig, A Vangsted, J Zeuthen and C Geisler, "Assembly of the T-cell antigen receptor. Participation of the CD3 omega chain.", Journal of Immunology, (19930000), vol. 151, pages 870 - 879, XP055718970-
OPPOSITION- Anonymous, "BCMA (Vicky-):sc-57037", (13-08-2009), SANTA CRUZ BIOTECHNOLOGY, URL: http://datasheets.scbt.com/sc-57037.pdf, XP055720861-
OPPOSITION- Anonymous, "BMCA (human) monoclonal antbody (Vicky-1)", Enzo Product Data Sheet, (20191220), XP055720869-
OPPOSITION- Anonymous, "Human BCMA/TNFRSF17 Antibody Catalog Number: MAB193", (20180702), R&D Systems, URL: https://resources.rndsystems.com/pdfs/datasheets/mab193.pdf, (20200807), XP055720877-
OPPOSITION- Anonymous, "Human BCMA/TNFRSF17 antibody", R AND D SYSTEMS A BIOTECHNE BRAND, (2016000), page 1, XP055718523-
OPPOSITION- BAEUERLE et al., "BiTE: Teaching antibodies to engage T-cells for cancer therapy", Current Opinion in Molecular Therapeutics, (20090000), vol. 11, no. 1, pages 22 - 30, XP009151509-
OPPOSITION- BELLUCCI et al., "Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highlv expressed antigens", Blood, (20040115), vol. 103, no. 2, pages 656 - 663, XP055744212-
OPPOSITION- BELLUCCI et al., "Complete response to donor lymphocyte infusion in patients with multiple myeloma is associated with antibody response to BCMA, a plasma cell membrane recepto r", Blood, (20031116), vol. 102, no. 11, pages 192a - 193a-
OPPOSITION- BELLUCCI et al., "Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma- cell membrane receptor", Blood, (20050515), vol. 105, no. 10, pages 3945 - 3950, XP002581271-
OPPOSITION- CHAMES et al., "Bispecific antibodies for cancer therapy", Current Opinion in Drug Discovery & Development, (20090000), vol. 12, no. 2, pages 276 - 283, XP009145632-
OPPOSITION- FITZGERALD K A ET AL, "CYTOKINE FACTSBOOK PASSAGE", CYTOKINE FACTSBOOK, US, (20010101), vol. 1, pages 150 - 152, XP008087763-
OPPOSITION- "Homo sapiens CD 3e molecule ( CD 3E), mRNA", GenBank, Database accession no. NM _ 000733-
OPPOSITION- "Homo sapiens gene for BCMA, complete cds", GenBank, Database accession no. AB052772-
OPPOSITION- L. K. Clayton, L. D'Adamio, F. D. Howard, M. Sieh, R. E. Hussey, S. Koyasu, E. L. Reinherz, "CD3η and CD3ζ are alternatively spliced products of a common genetic locus and are transcriptionally and/or post-transcriptionally regulated during T-cell development", Immunology, (19910000), vol. 88, pages 5202 - 5206, XP055718964-
OPPOSITION- MAB193 datasheet-
OPPOSITION- Maureen C. Ryan, Michelle Hering, David Peckham, Charlotte F. McDonagh, Lindsay Brown, Kristine M. Kim, Damon L. Meyer, Roger F. Zabinski, Iqbal S. Grewal and Paul J. Carter, "Antibody targeting of B-cell maturation antigen on malignant plasma cells", Molecular Cancer Therapeutics, (20070000), vol. 6, no. 11, pages 3009 - 3018, XP002581270-
OPPOSITION- MÃœLLER et al., "Bispecific antibodies for cancer immunotherapy", Biodrugs, (20100000), vol. 24, no. 2, pages 89 - 98, XP055744248-
OPPOSITION- MÃœLLER et al., "Recombinant bispecific antibodies for cellular cancer immunotherapy", Current Opinion in Molecular Therapeutics, (20060000), vol. 9, no. 4, pages 319 - 326, XP009169663-
OPPOSITION- RYAN et al., "Antibody targeting of B- cell maturation antigen on malignant plasma cells", Mol Cancer Ther, (20070000), vol. 6, no. 11, pages 3009 - 3018, XP002581270-
OPPOSITION- RYAN MAUREEN C; ET AL, "Antibody targeting of B-cell maturation antigen on malignant plasma cells", Molecular Cancer Therapeutics, (20071101), vol. 6, no. 11, pages 3009 - 3018, XP002581270-
OPPOSITION- RYAN MAUREEN C, ET AL, "Antibody targeting of B-cell maturation antigen on malignant plasma cells.", Molecular Cancer Therapeutics,, American Association for Cancer Research, US, (20071101), vol. 6, no. 11, doi:10.1158/1535-7163.MCT-07-0464, ISSN 1535-7163, pages 3009 - 3018, XP002581270-
OPPOSITION- RYAN MAUREEN C, ET AL, "Antibody targeting of B-cell maturation antigen on malignant plasma cells.", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US, (20071101), vol. 6, no. 11, ISSN 1535-7163, pages 3009 - 3018, XP002581270-
OPPOSITION- RYAN MAUREEN C, ET AL, "Antibody targeting of B-cell maturation antigen on malignant plasma cells.", Molecular Cancer Therapeutics, US, (20071101), vol. 6, no. 11, ISSN 1535-7163, pages 3009 - 3018, XP002581270-
OPPOSITION- Steven A Frank, "Part II: Molecular Processes. 4 Specificity and Cross-Reactivity", Immunology and Evolution of Infectious Disease, Princeton University Press, (20020101), vol. 3, pages 33 - 56, ISBN 978-0-691-09595-0, XP055524479-
OPPOSITION- TARTE et al., "BAFF is a survival factor for multiple myeloma cells", Myeloma Biology, (20020000), vol. II, page 811 a-
OPPOSITION- THAKUR et al., "Cancer therapy with bispecific antibodies: Clinical experience", Current Opinion in Molecular Therapeutics, (20100000), vol. 12, no. 3, pages 340 - 349, XP009145639-
OPPOSITION- VICKY-1 et al., datasheets (Santa Cruz Biotechnology and Enzo Life Sciences-
OPPOSITION- Vidal-Laliena, M. ; Romero, X. ; March, S. ; Requena, V. ; Petriz, J. ; Engel, P., "Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry", CELLULAR IMMUNOLOGY, US, (20050701), vol. 236, no. 1-2, ISSN 0008-8749, pages 6 - 16, XP027189874-
OPPOSITION- Matthew J Betts, Russell Robert B, "Amino Acid Properties and Consequences of Substitutions", Bioinformatics for Geneticists, Chichester, UK, John Wiley & Sons, Ltd, (20030101), pages 289 - 316, doi:10.1002/9780470059180.ch13, ISBN 978-0-470-02619-9, XP055515752
OPPOSITION- WALLWEBER et al., "The Crystal Structure of A Proliferation-inducinq Liqand, APRIL", Journal of Molecular Biology, (20040000), vol. 343, pages 283 - 290, XP004576830
OPPOSITION- Bossen, C. Schneider, P., "BAFF, APRIL and their receptors: Structure, function and signaling", SEMINARS IN IMMUNOLOGY., US, (20061001), vol. 18, no. 5, doi:10.1016/j.smim.2006.04.006, ISSN 1044-5323, pages 263 - 275, XP005614343
OPPOSITION- KUFER et al., "Review - A revival of bispecific antibodies", Trends in Biotechnology, (20040000), vol. 22, no. 5, pages 238 - 244, XP004504363
OPPOSITION- BODMER et al., "Review - The molecular architecture of the TNF superfamily", Trends in Biochemical Sciences, (20020000), vol. 27, no. 1, pages 19 - 26, XP002276709
OPPOSITION- HIPP et al., "A novel BCMAlCD3 bispecific T- cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo", Leukemia, (20170000), vol. 31, doi:10.1038/leu.2016.388, pages 1743 - 1751, XP055547607
OPPOSITION- Hipp S; Y-T Tai; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam P J; Anderson K C; Friedrich M, "A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo", Blood Cancer Journal, (20170801), vol. 31, no. 8, pages 1743 - 1751, XP055547607
OPPOSITION- S Hipp, Y-T Tai, D Blanset, P Deegen, J Wahl, O Thomas, B Rattel, P J Adam, K C Anderson, M Friedrich, "A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo", Blood Cancer Journal,, Nature Publishing Group UK, London, (20170801), vol. 31, no. 8, doi:10.1038/leu.2016.388, ISSN 0887-6924, pages 1743 - 1751, XP055547607
OPPOSITION- S Hipp, Y-T Tai, D Blanset, P Deegen, J Wahl, O Thomas, B Rattel, P J Adam, K C Anderson, M Friedrich, "A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo", Leukemia, London, (20170801), vol. 31, no. 8, doi:10.1038/leu.2016.388, ISSN 0887-6924, pages 1743 - 1751, XP055547607
OPPOSITION- LIU et al., "Ligand-receptor binding revealed by the TNF family member TALL- 1", Nature, (20030000), vol. 423, doi:10.1038/nature01543, pages 49 - 56, XP002328536
OPPOSITION- DILLON et al., "An APRIL to remember: Novel TNF ligands as therapeutic tarqets", Nat Rev, (20060300), vol. 5, doi:10.1038/NRD1982, pages 235 - 246, XP002663210
OPPOSITION- D Hönemann, P Kufer, M M Rimpler, M Chatterjee, S Friedl, F Riecher, K Bommert, B Dörken, R C Bargou, "A novel recombinant bispecific single-chain antibody, bscWue-1 × CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells", Blood Cancer Journal, Nature Publishing Group UK, London, London, (20040301), vol. 18, no. 3, doi:10.1038/sj.leu.2403264, ISSN 0887-6924, pages 636 - 644, XP055741420
OPPOSITION- KJER-NIELSEN et al., "Crystal structure of the human T cell receptor CD3 heterodimer complexed to the therapeutic mAb OKT3", Proceedings of the National Academy of Sciences, (20040000), vol. 101, pages 7675 - 7680, XP055329073
OPPOSITION- PATEL D R,ET AL, "Engineering an APRIL-specific B cell maturation antigen", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US, (20040416), vol. 279, no. 16, doi:10.1074/jbc.M312316200, ISSN 0021-9258, pages 16727 - 16735, XP002318161
OPPOSITION- PATEL et al., "Engineering an APRIL-specific B Cell Maturation Antigen", Journal of Biological Chemistry, (20040000), vol. 279, no. 16, doi:10.1074/jbc.M312316200, pages 16727 - 16735, XP002318161
OPPOSITION- HYMOWITZ et al., "Structures of APRIL-Receotor Complexes", Journal of Biological Chemistry, (20050000), vol. 280, no. 8, doi:10.1074/jbc.M411714200, pages 7218 - 7227, XP002373779
OPPOSITION- HYMOWITZ et al., "Structures of APRIL-receptor complexes - Like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding", Journal of Biological Chemistry, (20050000), vol. 280, pages 7218 - 7227, XP002373779
OPPOSITION- HYMOWITZ S G; ET AL, "Structures of APRIL-receptor complexes - Like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding", Journal of Biological Chemistry, (20050225), vol. 280, no. 8, pages 7218 - 7227, XP002373779
OPPOSITION- HYMOWITZ S G, ET AL., "Structures of APRIL-receptor complexes - Like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US, (20050225), vol. 280, no. 8, doi:10.1074/jbc.M411714200, ISSN 0021-9258, pages 7218 - 7227, XP002373779
OPPOSITION- MOREAUX et al., "APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop", Eur J Heamatol, (20090000), vol. 83, doi:10.1111/j.1600-0609.2009.01262.x, pages 119 - 129, XP055377292
OPPOSITION- KONTERMANN, "Invited review - Recombinant bispecific antibodies for cancer therapy", Acta Pharmacologica Sinica, (20050000), vol. 26, no. 1, pages 1 - 9, XP002426874
OPPOSITION- KONTERMANN ROLAND E, "Recombinant bispecific antibodies for cancer therapy", Acta Pharmacologica Sinica,, (20050101), vol. 26, no. 1, pages 1 - 9, XP002426874
OPPOSITION- KONTERMANN ROLAND E, "Recombinant bispecific antibodies for cancer therapy", Acta Pharmacologica Sinica, GB, (20050101), vol. 26, no. 1, doi:10.1111/j.1745-7254.2005.00008.x, ISSN 1671-4083, pages 1 - 9, XP002426874
OPPOSITION- KONTERMANN ROLAND E, "Recombinant bispecific antibodies for cancer therapy", Acta Pharmacologica Sinica, Nature Publishing Group, GB, GB, (20050101), vol. 26, no. 1, doi:10.1111/j.1745-7254.2005.00008.x, ISSN 1671-4083, pages 1 - 9, XP002426874
OPPOSITION- BAEUERLE et al., "Bispecific T- cell engaging antibodies for cancer therapy", Cancer Research, (20090000), vol. 69, no. 12, doi:10.1158/0008-5472.CAN-09-0547, pages 4941 - 4944, XP002665118
OPPOSITION- BAEUERLE PATRICK A; REINHARDT CARSTEN, "Bispecific T-cell engaging antibodies for cancer therapy", CANCER RESEARCH, (20090615), vol. 69, no. 12, pages 4941 - 4944, XP002665118
OPPOSITION- Panowski, Siler H., Tracy C Kuo, Yi Zhang, Amy Chen, Tao Geng, Laura Aschenbrenner, Cris Kamperschroer, Edward Pascua, Wei Chen, Kathy Delaria, Santiago Farias, Marjorie Bateman, Russell G Dushin, Sherman M. Chin, Thomas J Van Blarcom, Yik Andy Yeung, Kevin C Lindquist, Allison G. Chunyk, Bing Kuang, Bora Han, Michael Mirsky, Ingrid Pardo, Bernard Buetow, Thomas G. Martin, Jeffrey L. Wolf, David Shelton, Arvind Rajpal, Pavel Strop, Javier Chaparro-Riggers And Barbra J Sasu, "Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma", Molecular cancer therapeutics, (20190821), pages 1 - 13, XP055718531
OPPOSITION- A. J. Novak, "Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival", Blood, (20040115), vol. 103, no. 2, doi:10.1182/blood-2003-06-2043, ISSN 00064971, pages 689 - 694, XP055004448
OPPOSITION- Novak A J, "Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival", Blood, (20040115), vol. 103, no. 2, pages 689 - 694, XP055004448
OPPOSITION- NOVAK et al., "Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival", Blood, (20040000), vol. 103, no. 2, doi:10.1182/blood-2003-06-2043, pages 689 - 694, XP055004448
OPPOSITION- LEIBA et al., "Activation of b- cell maturation antigen (BCMA) on human multiple myeloma cells by a proliferation-inducing ligand (APRIL) promotes myeloma cell function in the bone marrow microenvironment", Blood, (20070000), vol. 110, no. 11, page 1503, XP055744224
OPPOSITION- BAEUERLE et al., "BiTE: A new class of antibodies that recruit T-cells", Drugs of the Future, (20080000), vol. 33, no. 2, doi:10.1358/DOF.2008.033.02.1172578, pages 137 - 147, XP002667644
OPPOSITION- CHOI et al., "Bispecific antibodies engaqe T cells for antitumor immunotherapy", Expert Opinion on Biological Therapy, (20110000), vol. 11, no. 7, pages 843 - 853, XP009169599
OPPOSITION- CHAMES et al., "Bispecific antibodies for cancer therapy. The light at the end of the tunnel?", mAbs, (20090000), vol. 1, pages 539 - 547, XP002688758

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents